ASX:SUD

Suda Pharmaceuticals Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume842,145 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Receive SUD News and Ratings via Email

Sign-up to receive the latest news and ratings for Suda Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


About Suda Pharmaceuticals

Suda Pharmaceuticals Ltd engages in the development of drug delivery technology in Australia, India, Europe and Korea. It offers ZolpiMist, an oro-mucosal spray formulation of zolpidem tartrate marketed under the brand name of Ambien or Stilnox, a non-benzodiazepine prescribed for the short-term treatment of insomnia. The company's product pipeline includes Sumatriptan, an oral spray formulation for the treatment of acute migraine; and anagrelide, a platelet lowering agent for use in thrombosis, which is used for the treatment of cancer. Suda Pharmaceuticals Ltd has license and supply agreement with Teva Pharmaceuticals International GmbH and Mitsubishi Tanabe Pharma Singapore for ZolpiMist oral spray; product development, licence, and supply agreement with Cann Pharmaceutical Australia Ltd for the development of novel oral spray of pharmaceutical-grade cannabinoid derivatives for the treatment of drug resistant epilepsy, melanoma, and motion sickness; and feasibility and option agreement with Zelira Therapeutics for the use of cannabinoids for a range of uses, including insomnia, autism, opioid reduction, anxiety, pain, and cancer. The company also has a feasibility study and option agreement with Laboratorios Ordesa, S.L. The company was formerly known as Suda Limited and changed its name to Suda Pharmaceuticals Ltd in November 2017. Suda Pharmaceuticals Ltd was incorporated in 1999 and is headquartered in Osborne Park, Australia.

Headlines

No headlines for this company have been tracked by MarketBeat.com

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.99 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Suda Pharmaceuticals (ASX:SUD) Frequently Asked Questions

What stocks does MarketBeat like better than Suda Pharmaceuticals?

Wall Street analysts have given Suda Pharmaceuticals a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Suda Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Suda Pharmaceuticals' key executives?

Suda Pharmaceuticals' management team includes the following people:
  • Dr. Michael Baker, CEO, MD, CTO & Director
  • Mr. Stephen John Carter, Consultant
  • Mr. David Phillips, Exec. Director
  • Mr. Phillip Hains C.A., M.B.A., B Bus, CA, MBA, Company Sec. & CFO (Age 60)
  • Dr. Richard Franklin, Project Director & Member of Scientific Advisory Board
  • Tony Macintyre, GM & CTO

Who are some of Suda Pharmaceuticals' key competitors?

What is Suda Pharmaceuticals' stock symbol?

Suda Pharmaceuticals trades on the ASX under the ticker symbol "SUD."

How much money does Suda Pharmaceuticals make?

Suda Pharmaceuticals has a market capitalization of $0.00 and generates $563,927.00 in revenue each year.

What is Suda Pharmaceuticals' official website?

The official website for Suda Pharmaceuticals is sudapharma.com.

How can I contact Suda Pharmaceuticals?

The company can be reached via phone at 61 8 6142 5555.


This page was last updated on 8/5/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.